FindTrial
Sign In

Fludarabine (FLU)

DRUG10 trials

Sponsors

Masonic Cancer Center, University of Minnesota, Nanfang Hospital, Southern Medical University, Shanghai NK Cell Technology Co., LTD, Institute of Hematology & Blood Diseases Hospital, China, Anhui Provincial Hospital

Conditions

AMLAcute Lymphocytic LeukemiaAcute Myeloid LeukemiaAdvanced Solid TumorsAllogeneic Hematopoietic Stem Cell TransplantationAplastic Anemia IdiopathicBiphenotypic/Undifferentiated LeukemiaBone Marrow Failure

Phase 1

A Phase I Study of NK042 Cell Injection in Advanced Solid Tumors
RecruitingNCT06773091
Shanghai NK Cell Technology Co., LTDAdvanced Solid Tumors
Start: 2025-02-07End: 2026-12-31Target: 76Updated: 2025-02-11
Allogeneic CD7 CAR γδ T Cells Therapy Recurrent/Refractory Leukemia
Not yet recruitingNCT07120607
Anhui Provincial HospitalLeukemia
Start: 2025-08-18End: 2027-12-31Target: 9Updated: 2025-08-13
QH101 Cell Therapy Relapsed/Refractory(R/R) Acute Myeloid Leukemia(AML) and Myelodysplastic Syndromes(MDS)
Not yet recruitingNCT07131085
Anhui Provincial HospitalAML, MDS
Start: 2025-08-15End: 2027-12-31Target: 9Updated: 2025-08-20

Phase 2

Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
RecruitingNCT03579875
Masonic Cancer Center, University of MinnesotaBone Marrow Failure, Dyskeratosis Congenita, Fanconi Anemia +5
Start: 2018-11-13End: 2029-01-05Target: 48Updated: 2026-01-30
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
Active, not recruitingNCT03674411
Masonic Cancer Center, University of MinnesotaAcute Lymphocytic Leukemia, Acute Myeloid Leukemia, Biphenotypic/Undifferentiated Leukemia +8
Start: 2019-01-02End: 2026-12-01Updated: 2026-01-06
G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for RAEB-1,REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT
NCT04713956
Nanfang Hospital, Southern Medical UniversityAllogeneic Hematopoietic Stem Cell Transplantation, Conditioning, Myelodysplastic Syndrome
Start: 2021-01-15End: 2024-07-31Target: 242Updated: 2021-01-19
G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for Secondary Acute Myeloid Leukemia Undergoing Allo-HSCT
NCT05449899
Nanfang Hospital, Southern Medical UniversityAllogeneic Hematopoietic Stem Cell Transplantation, Conditioning, Secondary Acute Myeloid Leukemia Evolving From MDS
Start: 2022-07-31End: 2024-12-31Target: 232Updated: 2022-07-08
G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for High-risk MDS Undergoing Allo-HSCT
NCT05453552
Nanfang Hospital, Southern Medical UniversityAllogeneic Hematopoietic Stem Cell Transplantation, Conditioning, Myelodysplastic Syndrome
Start: 2022-07-01End: 2024-12-31Target: 242Updated: 2023-03-21
VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT
Not yet recruitingNCT07052422
Nanfang Hospital, Southern Medical UniversityConditioning, Hematopoietic Stem Cell Transplantation (HSCT), Myeloid Malignancies +1
Start: 2025-07-15End: 2029-12-31Target: 160Updated: 2025-07-04
Efficacy and Safety of UCBT With TMI -Based Conditioning Regimen for Adults With Refractory/Relapsed Aplastic Anemia
Not yet recruitingNCT07078721
Institute of Hematology & Blood Diseases Hospital, ChinaAplastic Anemia Idiopathic
Start: 2025-07-20End: 2028-06-30Target: 11Updated: 2025-07-22

Related Papers

TCRα/β Depleted Mobilized Pbscs without Calcineurin Inhibitors in Patients with Fanconi Anemia
Blood2024-11-05
Mgta-456, a Cell Therapy Utilizing Expansion of CD34+ Hematopoietic Stem Cells (HSC), Improves HLA Matching for Adult Recipients, Promotes Faster Hematopoietic Recovery and Enables Uniform Engraftment with Less Acute Graft-Vs-Host Disease (GVHD)
Biology of Blood and Marrow Transplantation2020-01-23
Mgta-456, an Aryl Hydrocarbon Receptor (AHR) Antagonist Based Expansion of CD34+ Hematopoietic Stem Cells (HSC), Permits Selection of Better HLA Matched Cord Blood Units (CBUs) and Promotes Faster Neutrophil Recovery and Uniform Engraftment with Potentially Less Acute Graft-Vs-Host Disease (GVHD)
Blood2019-11-134 citations